• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ORTX

ORTX

Orchard Therapeutics plc

NASDAQHealthcareBiotechnologyGB

USD16.70

+0.05 (+0.30%)

Company Profile

CEO

Hubert Baburaj Gaspar

IPO Date

2018-10-31

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

GB

Market Metrics

Open

$16.65

Prev. Close

$16.65

Day Low

$16.64

Day High

$16.72

52W Low

$4.24

52W High

$16.72

Market Cap

$0.38B

Volume

0.37M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

52.7%

Avg Negative

1.4%

Avg Neutral

46.1%

News Feed

Orchard Therapeutics, Pharming Ink Development Pact For Gene Therapy

Benzinga·7/1/2021·↑ positive

Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema

GlobeNewsWire·7/1/2021·↑ positive

Orchard Therapeutics Issues Updates On Gene Therapy Programs

Benzinga·6/29/2021·↑ positive

Orchard Therapeutics Posts Long-Term Data For Gene Therapy In Inherited Immune System Disorder

Benzinga·5/11/2021·↑ positive

Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy

GlobeNewsWire·4/28/2021·↑ positive

Orchard Therapeutics: Curative Medicines For Immune-Related Diseases

Seeking Alpha·3/24/2021·↑ positive

Recap: Orchard Therapeutics Q4 Earnings

Benzinga·3/2/2021·↑ positive

Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021

GlobeNewsWire·2/25/2021·↑ positive

What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?

Zacks Investment Research·2/15/2021·↑ positive

Why Orchard Therapeutics Stock Is Jumping Today

The Motley Fool·2/9/2021·↑ positive